- Advanced search
- Immuno Portal
- Malaria Portal
tralokinumab is an approved drug (EMA & FDA (2021))
Compound class: Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions  Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology .
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.